HOME >> BIOLOGY >> NEWS
Common therapy for HIV associated with cervical abnormality regression

Among women infected with human immunodeficiency virus (HIV), a combination of antiretroviral drugs that helps boost the immune system is associated with the regression of a type of cervical abnormality that can eventually lead to cancer, according to a study in the July 21 issue of the Journal of the National Cancer Institute.

HIV infection is associated with an increased risk of abnormalities in the cervix called squamous intraepithelial lesions (SIL). In healthy women, the low-grade form of this type of abnormality often disappears on its own without treatment. Also, women who are HIV-positive are at an increased risk of infection with human papillomavirus (HPV), which are known to cause cervical cancer and its precursor lesions.

Highly active antiretroviral therapy (HAART) is a combination of several antiretroviral drugs that reduces the number of HIV particles in the bloodstream and helps boost immune system function. However, it is unclear whether the boost in immune status afforded by HAART improves the regression rates of SIL.

Linda Ahdieh-Grant, Ph.D., of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues analyzed data from the Women's Interagency HIV Study to examine the long-term effects of HAART on the regression of cervical SIL. Of the approximately 2,000 women who participated in the study, there were 312 women who had normal Pap smears at the time they entered the study and then, at some point during the 7 years of follow-up, were diagnosed with SIL.

The introduction of HAART was associated with a regression of SIL. Compared with women whose abnormality regressed, women whose lesions did not regress had more advanced HIV disease, including lower T-cell counts. Before women started HAART, the rate of disease regression was 0.0%; after HAART was introduced, the regression rate was 12.5%. However, the authors point out that the majority of the lesions in HIV-infected women, even among th
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Jul-2004


Page: 1 2

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common chemicals morphing into potential toxins in Arctic
4. Common worm provides insights into salmonella virulence
5. Common virus may contribute to uncommon bone disease in children
6. Common airborne substance makes asthmatics more sensitive to house dust mites: study
7. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
8. Common nutrients fed to pregnant mice altered their offsprings coat color
9. Common treatment for depression is safe and effective for Alzheimers patients
10. Common gene variant increases risk of atherosclerosis
11. Common thyroid cancer gene mutation found

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2019)... , ... February 20, 2019 , ... ... announced plans today to expand the company’s footprint in Frederick, MD after a ... have used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their ...
(Date:2/22/2019)... ... , ... Clean label food is not just another passing trend in the ... is quite common to spot consumers running their index finger across the back of ... label scrutiny. , More than ever, meat and poultry producers are working diligently ...
(Date:2/22/2019)... ... February 21, 2019 , ... ... implanted SpineFrontier’s SacroFuse system in conjunction with NanoFUSE’s Orthobiologic ... case represents the first time that either SacroFuse or NanoFUSE have been used ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... ... This free webinar will review strategies for data management in modular and adaptive ... build times by up to 30 percent, reducing cost while increasing quality, achieving clinical site ... need to migrate data – reducing risk and impact on trial success, trial teams, and ...
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO ... Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical ... as the fifth institution in Oklahoma to receive this prestigious endorsement. The ...
(Date:3/14/2019)... ... March 13, 2019 , ... The International Society for ... taking place in Brussels, Belgium on 25–26 September 2019. This event is a ... innovative approaches. , “Biopharmaceuticals have become a main pillar in the pharmaceutical ...
(Date:3/11/2019)... ... March 11, 2019 , ... USDM Life Sciences and Generis ... with built in GxP compliance for the life sciences industry. USDM Cloud Assurance ... continuous compliance for Generis’ flagship product, CARA. , Presentation One:, ...
Breaking Biology Technology:
Cached News: